Gates rounds up $94M for late-stage R&D work; Agios leaps into the clinic;

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Some folks might want to adjust their timelines on ARN-509. PhIII is coming. Item | Follow @JohnCFierce

@DamianFierce: Thanks to everyone cheering my trip to FierceBiotech! | Follow @DamianFierce

> The Bill & Melinda Gates Foundation has joined hands with JPMorgan Chase and a group of investors to form a $94 million fund to back late-stage work on new treatments for a slate of killers like malaria, tuberculosis and HIV. Report

> Agios Pharmaceuticals ($AGIO), which pulled off one of this year's hottest IPOs without any human data on its drugs, has dosed the first patient in a Phase I trial of AG-221. Story

> Sequenom says it is pondering the sale of its genetic analysis unit. Story | FierceMedicalDevices' take

Medical Device News

@FierceMedDev: At AdvaMed, European regulations are on many CEOs' minds. Editor's corner | Follow @FierceMedDev

@MarkHFierce: The debt ceiling/budget fight has given an opening to device tax opponents. They hope for a repeal before year-end. More | Follow @MarkHFierce

@MichaelGFierce: Alnylam heralds positive results for RNAi amyloidosis drug. Story | Follow @MichaelGFierce

> Edwards wins FDA nod to expand Sapien label. Story

> Federal debt ceiling fight opens window for device tax opponents. Report

> Medtronic's tech halves atrial fibrillation risk. More

Pharma News

@FiercePharma: Top story on our website this A.M.: Who are the richest biopharma execs? Not all the usual suspects. Article | Follow @FiercePharma

> GlaxoSmithKline's China sales set for 30% hit, analysts figure. More

> Servier offers $483M to buy out other Egis shareholders. Story

> Pfizer rolls out digital reps in U.K., hoping for access to primary-care docs. Article

Pharma Manufacturing News

@EricPFierce: After sales of Bydureon came up short, Bristol-Myers, AstraZeneca report manufacturing has too. Article | Follow @EricPFierce

> FDA warns Agila plant over torn gloves. Story

> Pharma squares off against compounders in lobbying fight. News

> J&J wins a bright spot after string of recalls. More

> FDA beefs up Indian staff in face of serious problems. Story

> U.K., Australia gather FDA intel on Ranbaxy ban. Report

Biotech Research News

@EmilyMFierce: $3.7M NIH program to fund biomedical research training. Item | Follow @EmilyMFierce

> Stem cell therapy protects vision in preclinical retinal disease study. More

> Pre-leukemia drug shows brain tumor regression in mice. News

> Stem cell reprogramming made easier by removing one protein. Report

> New compound kills tuberculosis bacterium in lab tests. Story

> NIH launches $45M Alzheimer's research effort, awards funds to 3 preclinical studies. Article

And Finally… Investigators at Johns Hopkins say that a repurposed drug already approved at the FDA was able to wipe out brain tumor cells in IDH1 mutant gliomas taken from humans. Release

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.